{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:53:05Z","timestamp":1768009985308,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007394","name":"Association Laurette Fugain","doi-asserted-by":"publisher","award":["2024\/11"],"award-info":[{"award-number":["2024\/11"]}],"id":[{"id":"10.13039\/100007394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["RS25\/75-76"],"award-info":[{"award-number":["RS25\/75-76"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["TADH27012"],"award-info":[{"award-number":["TADH27012"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Force H\u00e9mato"},{"name":"AstraZeneca, Beigene"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41375-025-02818-w","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:14:49Z","timestamp":1765278889000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["REL overexpression and sustained NF-\u03baB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"L\u00e9a","family":"Dehgane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphn\u00e9","family":"Krzisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wail","family":"Zeitouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casilda","family":"Hitier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8288-5217","authenticated-orcid":false,"given":"Kenza","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"P\u00e9rez Carretero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-4801","authenticated-orcid":false,"given":"Karim","family":"Maloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Bravetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Armand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-5612","authenticated-orcid":false,"given":"Delphine","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-9371","authenticated-orcid":false,"given":"Jes\u00fas-Mar\u00eda","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-1628","authenticated-orcid":false,"given":"Santos A.","family":"Susin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Nguyen-Khac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-7596","authenticated-orcid":false,"given":"Elise","family":"Chapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the French Innovative Leukemia Organization (FILO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2818_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2019000854","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel A, Fornecker L-M, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019;134:641\u20134.","journal-title":"Blood"},{"key":"2818_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","volume":"7","author":"JA Burger","year":"2016","unstructured":"Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.","journal-title":"Nat Commun"},{"key":"2818_CR3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/leu.2017.100","volume":"31","author":"A Cosson","year":"2017","unstructured":"Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung H-A, et al. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia. 2017;31:1625\u20139.","journal-title":"Leukemia"},{"key":"2818_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","volume":"1","author":"S Kadri","year":"2017","unstructured":"Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1:715\u201327.","journal-title":"Blood Adv"},{"key":"2818_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.leukres.2009.03.042","volume":"34","author":"E Chapiro","year":"2010","unstructured":"Chapiro E, Leporrier N, Radford-Weiss I, Bastard C, Mossafa H, Leroux D, et al. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res. 2010;34:63\u201368.","journal-title":"Leuk Res"},{"key":"2818_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714\u201326.","journal-title":"Cell"},{"key":"2818_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525\u201330.","journal-title":"Nature"},{"key":"2818_CR8","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/cam4.2123","volume":"8","author":"F Kostopoulou","year":"2019","unstructured":"Kostopoulou F, Gabillaud C, Chapiro E, Grange B, Tran J, Bouzy S, et al. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. Cancer Med. 2019;8:3131\u201341.","journal-title":"Cancer Med"},{"key":"2818_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2019.239947","volume":"106","author":"AC Leeksma","year":"2021","unstructured":"Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, Van der Kevie-Kersemaekers A-M, et al. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica. 2021;106:87\u201397.","journal-title":"Haematologica"},{"key":"2818_CR10","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","volume":"120","author":"J Edelmann","year":"2012","unstructured":"Edelmann J, Holzmann K, Miller F, Winkler D, B\u00fchler A, Zenz T, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120:4783\u201394.","journal-title":"Blood"},{"key":"2818_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2016.07.005","volume":"39","author":"L Mansouri","year":"2016","unstructured":"Mansouri L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Rosenquist R. NF-\u03baB activation in chronic lymphocytic leukemia: a point of convergence of external triggers and intrinsic lesions. Semin Cancer Biol. 2016;39:40\u201348.","journal-title":"Semin Cancer Biol"},{"key":"2818_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ord\u00f3\u00f1ez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101\u20135.","journal-title":"Nature"},{"key":"2818_CR13","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119:2854\u201362.","journal-title":"Blood"},{"key":"2818_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","volume":"4","author":"F Damm","year":"2014","unstructured":"Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088\u2013101.","journal-title":"Cancer Discov"},{"key":"2818_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00520-5","volume":"11","author":"M Quijada-\u00c1lamo","year":"2021","unstructured":"Quijada-\u00c1lamo M, Hern\u00e1ndez-S\u00e1nchez M, Rodr\u00edguez-Vicente A-E, P\u00e9rez-Carretero C, Rodr\u00edguez-S\u00e1nchez A, Mart\u00edn-Izquierdo M, et al. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. Blood Cancer J. 2021;11:127.","journal-title":"Blood Cancer J"},{"key":"2818_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/ajh.26578","volume":"97","author":"C P\u00e9rez-Carretero","year":"2022","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, Quijada-\u00c1lamo M, Mart\u00edn-Izquierdo M, Santos-M\u00ednguez S, et al. TRAF3 alterations are frequent in del-3\u2032IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022;97:903\u201314.","journal-title":"Am J Hematol"},{"key":"2818_CR17","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/s41375-023-02035-3","volume":"37","author":"L Jondreville","year":"2023","unstructured":"Jondreville L, Dehgane L, Doualle C, Smagghe L, Grange B, Davi F, et al. del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. Leukemia. 2023;37:2221\u201330.","journal-title":"Leukemia"},{"key":"2818_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1169397","volume":"13","author":"A O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell A, Pepper C, Mitchell S, Pepper A. NF-kB and the CLL microenvironment. Front Oncol. 2023;13:1169397.","journal-title":"Front Oncol"},{"key":"2818_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1947601911421925","volume":"2","author":"TD Gilmore","year":"2011","unstructured":"Gilmore TD, Gerondakis S. The c-Rel transcription factor in development and disease. Genes Cancer. 2011;2:695\u2013711.","journal-title":"Genes Cancer"},{"key":"2818_CR20","doi-asserted-by":"publisher","first-page":"31693","DOI":"10.1074\/jbc.M114.574517","volume":"289","author":"WH Neo","year":"2014","unstructured":"Neo WH, Lim JF, Grumont R, Gerondakis S, Su I. c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells. J Biol Chem. 2014;289:31693\u2013707.","journal-title":"J Biol Chem"},{"key":"2818_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/ijc.2910380413","volume":"38","author":"JV Melo","year":"1986","unstructured":"Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L, Catovsky D. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer. 1986;38:531\u20138.","journal-title":"Int J Cancer"},{"key":"2818_CR22","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, Sutton L-A, Ljungstr\u00f6m V, Capasso A, Pandzic T, Westr\u00f6m S, et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794\u2013806.","journal-title":"Blood Adv"},{"key":"2818_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W, Robak T, Ill\u00e9s \u00c1, Kater AP, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144:1061\u20138.","journal-title":"Blood"},{"key":"2818_CR24","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood-2017-08-803353","volume":"130","author":"X Zhao","year":"2017","unstructured":"Zhao X, Gao S, Wu Z, Kajigaya S, Feng X, Liu Q, et al. Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells. Blood. 2017;130:2762\u201373.","journal-title":"Blood"},{"key":"2818_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49529-x","volume":"15","author":"G Serrano","year":"2024","unstructured":"Serrano G, Berastegui N, D\u00edaz-Mazkiaran A, Garc\u00eda-Olloqui P, Rodriguez-Res C, Huerga-Dominguez S, et al. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide. Nat Commun. 2024;15:5272.","journal-title":"Nat Commun"},{"key":"2818_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41375-024-02224-8","volume":"38","author":"A Bonato","year":"2024","unstructured":"Bonato A, Chakraborty S, Bomben R, Canarutto G, Felician G, Martines C, et al. NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. Leukemia. 2024;38:1511\u201321.","journal-title":"Leukemia"},{"key":"2818_CR27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-024-02236-4","volume":"38","author":"J Bordini","year":"2024","unstructured":"Bordini J, Lenzi C, Frenquelli M, Morabito A, Pseftogas A, Belloni D, et al. I\u03baB\u03b5 deficiency accelerates disease development in chronic lymphocytic leukemia. Leukemia. 2024;38:1287\u201398.","journal-title":"Leukemia"},{"key":"2818_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 \u2014 from biology to targeted therapy. Nat Rev Clin Oncol. 2021;18:152\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"2818_CR29","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10238-023-01003-6","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu Z, Pan B, Miao Y, Li Y, Qin S, Liang J, et al. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia. Clin Exp Med. 2023;23:2651\u201362.","journal-title":"Clin Exp Med"},{"key":"2818_CR30","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB. Mol Cancer Ther. 2018;17:2564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"2818_CR31","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7:78896\u2013909.","journal-title":"Oncotarget"},{"key":"2818_CR32","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1038\/s41375-021-01237-x","volume":"35","author":"CR Miller","year":"2021","unstructured":"Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, et al. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia. 2021;35:3287\u201390.","journal-title":"Leukemia"},{"key":"2818_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science. 2024;383:eadi5798.","journal-title":"Science"},{"key":"2818_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326\u201337.","journal-title":"N Engl J Med"},{"key":"2818_CR35","doi-asserted-by":"crossref","unstructured":"Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol. 2024;43:788\u201399.","DOI":"10.1200\/JCO-24-02503"},{"key":"2818_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","volume":"30","author":"N Jain","year":"2024","unstructured":"Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, et al. Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax. Clin Cancer Res. 2024;30:498\u2013505.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02818-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02818-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02818-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:04:15Z","timestamp":1767985455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02818-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02818-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FN-K received research funding from BeiGene and AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}